The Pharmaceutical Market: Saudi Arabia


Saudi Arabia\' s transition to an increasingly privatised and comprehensive healthcare system will drive the demand for both patented and generic drugs . The country is investing heavily in healthcare infrastructure and we expect this will be borne out in double-digit growth forecasts across our three headline indicators.

Headline Expenditure Projections

  • Pharmaceuticals: SAR16.70bn (US$4.46bn) in 2011 to SAR18.95bn (US$5.06bn) in 2012; +13.5% in local currency and US dollar terms. Forecastbroadly unchanged from Q3 12.
  • Healthcare: SAR78.63bn (US$21.00bn) in 2011 to SAR91.20bn (US$24.35bn) in 2012; +16.0% in local currency and US dollar terms. Forecast broadly unchanged from Q3 12.
  • Medicaldevices: SAR5.54bn (US$1.48bn) in 2011 to SAR6.53bn (US$1.74bn) in 2012; +17.8% in local currency and US dollar terms. Forecastunchanged from Q3 12.



Risk/Reward Rating

Saudi Arabia\'s composite score remained steady in Q4 12 at 55.6. This places the country to firth place out of the 30 markets in the region. Its score is propped up by the country\'s wealth and a sizeable population (exceeding 28mn in 2011). Furthermore, its forecast growth rate is high due to favourable public and private healthcare investments. The government is also in the process of creating more public-private health partnerships and encouraging private health insurance uptake, which should provide momentum for drug sales.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

To Download Sample Report With TOC @ http://www.researchmoz.us/enquiry.php?type=S&repid=193655

Table of Contents
Rewards14
Risks14
Saudi Arabia - Market Summary16
Regulatory Regime18
Regulatory Developments19
Regional Regulatory Developments20
Free Trade Agreements21
Intellectual Property Regime21
IP Deficiencies23
Counterfeit Drugs25
OTC Drug Market25
Pricing Regime25
Reimbursement Regime26
Pricing System Reform26
Tendering Procedures27
Industry Trends And Developments29
Epidemiology29
Public Health Developments30


For More Information Kindly Contact:

ResearchMoz
Mr. Nachiket Ghumare,
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074

Comments

Popular posts from this blog

Global Organic Drinks Industrial Trend and Market Demand 2016-2020

Global Night Vision Devices Industrial Trend and Market Demand 2016-2020

Global Handling and Lifting Equipment Industrial Trend and Market Demand 2016-2020